Peptides for heart and circulation, ranked by human evidence

Peptides studied for blood pressure, heart failure, clotting and the blood vessels, including several approved cardiovascular medicines. They are ranked by an evidence score that weighs the grade of the evidence, the human trials counted in PubMed, and regulatory status — shown in the columns so any rank can be checked. A high score means a peptide is well studied and often approved for something, not that it is right, safe or legal for this goal. Nothing here is medical advice, and Grey Peptides sells nothing and links to no vendor. See all goals or the plainer browse by goal map.

Evidence grade

Regulatory status

Search name

Has a human trial on this page

56 peptides · sorted by evidence score (click a column to re-sort)

Peptide	Grade	Human studies	RCTs	Max trial phase	Regulatory	Dose	Score
Bivalirudin	High	1,765	288	Phase 4	FDA approved	intravenous →	100
Eptifibatide	High	1,189	189	Phase 4	FDA approved	intravenous →	100
Sotatercept	High	189	13	Phase 4	FDA approved	subcutaneous →	100
Angiotensin II	High	41,080	3,675	Phase 4	FDA approved	intravenous (central line preferred) →	90
Erythropoietin (EPO)	High	26,425	1,746	Phase 4	FDA approved	—	90
Vasopressin	High	23,749	1,349	Phase 4	FDA approved	intravenous →	90
ANP	High	16,152	1,226	Phase 4	Approved abroad	—	90
Desmopressin	High	5,337	319	Phase 4	FDA approved	—	90
Terlipressin	High	1,092	147	Phase 4	FDA approved	intravenous →	90
Icatibant	High	742	34	Phase 4	FDA approved	subcutaneous →	90
Thrombomodulin Alfa	High	59	9	Phase 3	Approved abroad	intravenous →	90
Enlicitide	High	34	5	Phase 3	FDA approved	oral →	90
Aprotinin	High	3,445	416	Phase 4	Discontinued	intravenous →	85
Lepirudin	High	475	11	Phase 4	Discontinued	intravenous →	85
Serelaxin	High	170	35	Phase 3	Discontinued	intravenous →	85
Desirudin	High	66	10	Phase 4	Discontinued	subcutaneous →	85
Peginesatide	High	52	2	Phase 4	Discontinued	intravenous or subcutaneous →	85
BNP	High	28,708	2,612	Phase 4	Diagnostic	—	75
Nesiritide	High	21,585	1,942	Phase 4	Discontinued	intravenous →	75
Ularitide	High	204	34	Phase 3	Discontinued	intravenous →	75
Ornipressin	Medium	157	12	—	Approved abroad	intravenous →	70
Danegaptide	Medium	11	1	Phase 2	In trials	—	70
Endothelin-1	Medium	18,754	1,181	Phase 4	Research only	—	65
Bradykinin	Medium	8,791	309	Phase 4	Research only	—	65
Angiotensin-(1-7)	Medium	1,426	32	Phase 4	Research only	—	65
Copeptin	Medium	1,380	99	Phase 4	Research only	—	65
Urocortin	Medium	594	6	Phase 2	Research only	—	65
Vessel dilator	Medium	118	1	—	Research only	—	65
Lixivaptan	Medium	93	11	Phase 3	Discontinued	oral →	65
Selepressin	Medium	22	1	Phase 3	Discontinued	intravenous →	65
Rotigaptide	Medium	15	2	Phase 2	Discontinued	intra-arterial (research study) →	65
Carperitide	Medium	539	33	Phase 4	Approved abroad	—	60
Felypressin	Medium	171	27	Phase 4	Approved abroad	local submucosal injection (dental) →	60
Pegmolesatide	Medium	6	0	Phase 4	Approved abroad	subcutaneous →	60
CGRP	Medium	9,803	561	Phase 4	Research only	—	55
Adrenomedullin	Medium	2,757	84	Phase 2	Research only	—	55
Apelin	Medium	1,675	42	Phase 4	Research only	—	55
Cenderitide	Low	29	2	Phase 2	In trials	—	50
Urotensin II	Low	579	10	Phase 2	Research only	—	45
Goralatide	Low	178	10	Phase 2	Research only	—	45
Catestatin	Low	174	1	Phase 4	Research only	—	45
Secretoneurin (SN)	Low	153	1	—	Research only	—	45
Urocortin 2	Low	129	2	—	Research only	intravenous →	45
D-4F	Low	42	1	—	Research only	oral →	45
Vasostatin (Chromogranin A)	Low	32,893	4,614	Phase 4	Research only	—	35
Elabela	Low	6,423	430	Phase 4	Research only	—	35
CNP	Low	996	29	Phase 4	Research only	—	35
PAMP (Proadrenomedullin N-terminal 20 Peptide)	Low	819	7	—	Research only	—	35
Salusin-beta	Low	81	1	Phase 4	Research only	—	35
Teprotide	Low	68	0	—	Research only	intravenous →	35
Chromofungin	Low	15	0	—	Research only	—	35
Adrenomedullin 2	Low	170	0	Phase 2	Research only	—	25
Salusin-alpha	Low	63	0	Phase 4	Research only	—	25
Urotensin II-related peptide	Low	38	0	—	Research only	—	25
B7-33	Low	10	0	—	Preclinical	—	25
Serpinin	Low	6	0	—	Research only	—	25

Other goals: Weight loss and metabolism · Healing, injury and recovery · Skin and hair · Focus, mood and the brain · Growth hormone and body composition · Sexual and reproductive health · Longevity and cell health · Immune defence and infection · Diagnostic and research tools · In development

How the evidence score works

Evidence score (0-100), a transparent ranking aid, not a verdict. grade: high=60, medium=40, low=20, ungraded=0. Human trial: an on-site read-and-cited randomized or clinical trial = +15, else any PubMed human-indexed record = +5, else 0. RCT literature: PubMed lists >=1 randomized controlled trial = +10. Regulatory: FDA-approved = +15, in trials / approved-abroad / in development = +5, else 0. Every component is stored on each record so the number can be re-derived; volume and grade are shown together so neither misleads.

“Human studies” and “RCTs” are PubMed record counts for the peptide (read 2026-11-07 from the counts behind the Evidence Explorer); a count is how much research exists and of what kind, never proof a peptide works. “Grade” is our editorial reading of the evidence — see how we grade evidence. The “Dose” column links to the entry for each peptide that carries a dose from a regulator’s label or a published human study — where the amount is shown with its source; the amount is never reprinted here without that source, and many research peptides have no human dose, shown as —. Of 660 peptides, 607 have at least one human-indexed PubMed record, 324 cite a human trial on their page, 124 are FDA-approved, and 271 carry a sourced dose.